Skip to main
ACAD

ACADIA Pharma (ACAD) Stock Forecast & Price Target

ACADIA Pharma (ACAD) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 32%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 5%

Bulls say

Acadia Pharmaceuticals Inc. has reported a strong quarter characterized by heightened healthcare provider (HCP) and patient engagement, which supports increased awareness and demand for its products, particularly NUPLAZID, prompting management to enhance its customer-facing team by 30% in 1Q26. The company has narrowed its revenue guidance for NUPLAZID to a range of $1.07 - $1.095 billion, reflecting a favorable reception from a direct-to-consumer (DTC) campaign, while also anticipating significant growth opportunities in the adult patient segment as it represents 60% of the current market share. Additionally, initial positive impacts from the sales force expansion are expected to yield meaningful benefits into 2026, reinforcing confidence in the company's financial performance moving forward.

Bears say

ACADIA Pharmaceuticals Inc. faces significant commercial risks that contribute to a negative outlook on its stock, primarily linked to potential stagnation in the growth of its core product, NUPLAZID, which may not meet revenue expectations in future clinical studies or regulatory approvals. There are concerns regarding the stalled launch of DAYBUE for Rett syndrome and the possibility of disappointing outcomes for other pipeline drugs, which could hinder the company’s ability to penetrate the market successfully. Financial performance may also be challenged, as evidenced by 3Q25 revenues of $101.1 million falling slightly below consensus expectations, highlighting the risks associated with its key products and the reliance on successful commercialization strategies.

ACADIA Pharma (ACAD) has been analyzed by 19 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ACADIA Pharma (ACAD) Forecast

Analysts have given ACADIA Pharma (ACAD) a Buy based on their latest research and market trends.

According to 19 analysts, ACADIA Pharma (ACAD) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ACADIA Pharma (ACAD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.